TY - JOUR
T1 - Tissue biomarkers in nonmuscle-invasive bladder cancer
T2 - any role in clinical practice?
AU - Bruchbacher, Andreas
AU - Soria, Francesco
AU - Hassler, Melanie
AU - Shariat, Shahrokh F
AU - D'Andrea, David
N1 - Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - PURPOSE OF REVIEW: To summarize recent findings on tissue biomarkers for nonmuscle-invasive bladder cancer (NMIBC) with an emphasis on their prognostic and predictive role.RECENT FINDINGS: Accurate risk stratification is essential and the major driver in patient counseling regarding surveillance and decision making relative to therapeutic strategies. In NMIBC, there is an unmet need for improving the accuracy of current prognostic and predictive models, which rely only on clinicopathologic features and do not reflect the biological heterogeneity of the cancer in each individual. Studies continuously shed novel light on some processes involved in cancerogenesis, host response and interactions in the tumor's own microenvironment, which may be considered as potential biomarkers and targets for future directed therapies.SUMMARY: Biomarkers are necessary to transform bladder cancer management and usher in the age of personalized medicine. The clinical use is, however, still limited because of heterogeneity in study design, staining methods and an overall lacking adherence to a structured biomarker testing process.
AB - PURPOSE OF REVIEW: To summarize recent findings on tissue biomarkers for nonmuscle-invasive bladder cancer (NMIBC) with an emphasis on their prognostic and predictive role.RECENT FINDINGS: Accurate risk stratification is essential and the major driver in patient counseling regarding surveillance and decision making relative to therapeutic strategies. In NMIBC, there is an unmet need for improving the accuracy of current prognostic and predictive models, which rely only on clinicopathologic features and do not reflect the biological heterogeneity of the cancer in each individual. Studies continuously shed novel light on some processes involved in cancerogenesis, host response and interactions in the tumor's own microenvironment, which may be considered as potential biomarkers and targets for future directed therapies.SUMMARY: Biomarkers are necessary to transform bladder cancer management and usher in the age of personalized medicine. The clinical use is, however, still limited because of heterogeneity in study design, staining methods and an overall lacking adherence to a structured biomarker testing process.
KW - Administration, Intravesical
KW - Antineoplastic Agents/administration & dosage
KW - Biomarkers, Tumor/analysis
KW - Carcinogenesis/pathology
KW - Chemotherapy, Adjuvant/methods
KW - Cystectomy
KW - Guideline Adherence
KW - Humans
KW - Neoplasm Invasiveness/pathology
KW - Practice Guidelines as Topic
KW - Predictive Value of Tests
KW - Prognosis
KW - Risk Assessment/methods
KW - Urinary Bladder/pathology
KW - Urinary Bladder Neoplasms/diagnosis
UR - http://www.scopus.com/inward/record.url?scp=85063269926&partnerID=8YFLogxK
U2 - 10.1097/MOU.0000000000000546
DO - 10.1097/MOU.0000000000000546
M3 - Review article
C2 - 30188332
SN - 0963-0643
VL - 28
SP - 584
EP - 590
JO - Current Opinion in Urology
JF - Current Opinion in Urology
IS - 6
ER -